# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Goldman Sachs Conference
- Goldman Sachs Conference
Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish o...
Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: ...
RBC Capital analyst Brian Abrahams reiterates Biogen (NASDAQ:BIIB) with a Outperform and maintains $317 price target.
Biogen Inc. (NASDAQ: BIIB) shares saw a notable uptick Monday afternoon, trading higher after the company revealed a new partne...